Topics

Overcoming primary resistance to checkpoint inhibition with selective inhibitor of TGFβ1

20:00 EDT 25 Mar 2020 | AAAS

(The Yates Network) While checkpoint inhibitor therapies (CPIs) have revolutionized the treatment of many cancers, the majority of patients do not respond. TGFβ has been implicated in primary resistance to checkpoints but development of therapies targeting broad TGFβ signaling has been hindered by dose-limiting cardiotoxicities. Preclinical data demonstrate highly selective inhibition of TGFβ1 activation with SRK-181 overcomes primary resistance to CPIs and leads to tumor regression or control, survival benefit, while avoiding the cardiotoxicities.

Original Article: Overcoming primary resistance to checkpoint inhibition with selective inhibitor of TGFβ1

NEXT ARTICLE

More From BioPortfolio on "Overcoming primary resistance to checkpoint inhibition with selective inhibitor of TGFβ1"

Quick Search